)
Gilead Sciences (GILD) investor relations material
Gilead Sciences Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Business outlook
Q3 delivered the strongest growth in more than a decade, with contributions across HIV, oncology and inflammation; management expects strong top- and bottom-line growth ahead.
HIV growth, oncology expansion and inflammation investment are diversifying the portfolio; BIKTARVY’s 2036 patent expiry is identified as the only major patent cliff.
Inflammation strategy
Oral alpha-4-beta-7 phase II data were described as potentially matching IV or injectable efficacy with good tolerability; development will pursue monotherapy and combinations in UC and IBD.
Tolerability may support use in moderate and milder disease; an in-licensed potent IL-23 peptide has potential for once-monthly dosing and possible oral combinations or co-formulation.
Inflammation is positioned as a 2030 growth opportunity; gamgertamig, a BCMAxCD3 B-cell depleter, could be the first potential launch, potentially in the early 2030s.
Oncology and Tubulis
Tubulis’ lead NaPi2b ADC targets ovarian cancer, with potential in endometrial and lung cancers; 5T4 and additional payloads are also in development.
Management highlighted the tight linker’s potential to support combinations with chemotherapy or other agents, across ovarian cancer and other tumor types.
Management expressed confidence in the ovarian cancer dose and expects to share more data in 2027; external combination partnerships remain an option.
- PrEP launches and anito-cel underpin a decade-long growth outlook despite the 2028 headwind.GILD
UBS Global Biopharma Conference 2026 - Anito-cel launch plans pair 200 centers with an earlier-line filing targeted for 2027.GILD
8th Annual Wolfe Research Healthcare Conference - Base sales grew 16%, lifting guidance; acquisitions and BIKTARVY pricing weigh on outlook.GILD
Q3 2026 - HIV and Oncology growth offset Veklury declines; FY24 ex-Veklury sales guidance rises.GILD
Q4 2023 - Strong HIV growth, new launches, and oncology advances drive portfolio momentum.GILD
Morgan Stanley 24th Annual Global Healthcare Conference - HIV and cell therapy franchises expand with new launches, pipeline progress, and strategic acquisitions.GILD
12th Annual Cantor Fitzgerald Global Healthcare Conference - Diversified pipeline advances in HIV, oncology, and inflammation set up multiple launches and key data.GILD
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 sales rose 10%, led by HIV and oncology, but IPR&D charges drove a net loss.GILD
Q2 2026 - Q3 2025 saw 3% revenue growth, strong HIV/liver sales, and a key Biktarvy patent win.GILD
Q3 2025
)
)
)
)
)
)
)
)